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Carboxyl-terminal-binding protein (CtBP)2 was originally
identified by virtue of its ability to interact with the carboxyl
terminus of the adenoviral protein E1A (1). Like other E1Abinding proteins, CtBP also interacts with a wide variety of cellular factors, many of which have been characterized as DNA
binding transcriptional repressors (2, 3). Thus, CtBP has been
categorized as a co-repressor. Genetic and biochemical studies
in Drosophila have shown that CtBP is required for the functions of several developmentally important transcription factors, including snail, kruppel, knirps, and Tramtrack69 (4 – 6).
In mammals, CtBP has two isoforms, CtBP1 and CtBP2, which
have been shown to participate in multiple developmental
pathways as well (2). A human disease, holoprosencephaly,
results from a mutation in the CtBP-interacting domain of
TGIF, a three amino acid loop extension (TALE) homeodomain
protein (7). The embryonic lethality of CtBP1 and two genetic
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knock-outs in mice supports the idea that these factors are
essential for mammalian development (8). Additionally, Evi-1,
an oncoprotein responsible for acute myelogenous leukemia,
requires interaction with CtBP to mediate transformation (9,
10).
Initially, CtBP was thought to negatively modulate the
oncogenic transformation activity of the E1A protein (1, 11).
Later, Grooteclaes and Frisch (12) demonstrated that this
occurs by sequestering CtBP from its cellular targets. Genes
regulated by CtBP have been identified serendipitously, for
the most part, by identifying certain CtBP binding transcription factor binding sites in gene promoters. In this manner,
for example, Grooteclaes and Frisch (12) determined that the
cell adhesion gene E-cadherin was regulated by CtBP through
the transcriptional repressor ZEB. Subsequent experiments
showed that reducing cellular CtBP levels via small interference
RNA up-regulates E-cadherin transcription (13). A more comprehensive analysis of possible CtBP targets was achieved using
microarray assays of mouse embryonic fibroblasts (MEFs)
derived from animals engineered to contain mutations in the
two mammalian CtBP isoforms (14). These studies supported
the idea that CtBP is critically involved in gene regulation in
mammalian systems. Of note, a group of genes up-regulated in
the knock-out MEFs have been linked to apoptosis, including
PERP (p53-effector related to pmp-22), p21, Noxa, and Bax.
Interestingly, despite the fact that these genes are known p53
targets, CtBP and p53 appear to act through distinct mechanisms. Similar to cells in which p53 has been activated, the
CtBP-null MEFs had an increased sensitivity to pro-apoptotic
stimuli (14). Thus, CtBP can be considered to be an anti-apoptotic factor. Disruption of the two CtBP isoforms in mice
causes lethality at day 8 of development due to a variety of
defects (8).
Relatively little is known about the regulation of transcriptional co-activators and co-repressors by intracellular signaling
pathways. As opposed to modifications of specific DNA binding factors, phosphorylation of co-regulators has the potential
to influence a large number of transcriptional programs. Such
pathways are just beginning to be characterized. The understanding of CtBP regulation, however, is rudimentary. Kagey
et al. (15) reported that CtBP was sumoylated on Lys-428 via
the actions of PC2, a polycomb group protein, and this modification could contribute to the regulation of CtBP localization.
The fact that CtBP is well known to be a phosphoprotein points
to another possible mode of regulation. Our studies demonstrated that the nuclear serine/threonine kinase termed homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates
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Genetic knock out of the transcriptional co-repressor carboxyl-terminal-binding protein (CtBP) in mouse embryonic
fibroblasts results in up-regulation of several genes involved
in apoptosis. We predicted, therefore, that a propensity toward
apoptosis might be regulated through changes in cellular CtBP
levels. Previously, we have identified the homeodomain-interacting protein kinase 2 as such a regulator and demonstrated
that HIPK2 activation causes Ser-422 phosphorylation and degradation of CtBP. In this study, we found that c-Jun NH2-terminal kinase 1 activation triggered CtBP phosphorylation on Ser422 and subsequent degradation, inducing p53-independent
apoptosis in human lung cancer cells. JNK1 has previously been
linked to UV-directed apoptosis. Expression of MKK7-JNK1 or
exposure to UV irradiation reduced cellular levels of CtBP via a
proteasome-mediated pathway. This effect was prevented by
JNK1 deficiency. In addition, sustained activation of the JNK1
pathway by cisplatin similarly triggered CtBP degradation.
These findings provide a novel target for chemotherapy in cancers lacking p53.

JNK Phosphorylation of CtBP Regulates Apoptosis

EXPERIMENTAL PROCEDURES
Plasmids—pcDNA3-MKK7-JNK1 was from R. Davis (University of Massachusetts, Worcester, MA). FLAG-CtBP and
PET24bCtBP were described previously (16). The CtBP S422A
mutation was created by QuikChangeTM mutagenesis.
Proteins—Bacterially purified JNK1 and p38 were activated
by their specific upstream kinases (immobilized for easy separation). His-CtBP (both wild type and S422A mutant) was
expressed in strain BL21(DE3) and purified by nickel-nitrilotriacetic acid affinity chromatography (Qiagen).
Cell Culture and Transfection—Cos 7, H1299, wild-type, and
JNK1-null MEFs were cultured in Dulbecco’s modified Eagle’s
medium plus 10% fetal bovine serum and antibiotics. The spectral characterization of the UV-B source and the mode of the
irradiation of cells with UV-B have been described previously
(24). Cisplatin, TNF␣, and proteasome inhibitor MG-132 were
from Sigma, R&D Systems, and Calbiochem, respectively. Cells
were transfected by Lipofectamine 2000 (Invitrogen). Cell morphology and the condensed nuclei by Hoechst staining were
examined by light and fluorescence microscopy, respectively.
In Vitro Kinase Assay—Recombinant CtBP and activated
JNK1 and p38 were incubated in kinase buffer (20 mM Hepes,
pH 7.4, 20 mM MgCl2, 25 mM ␤-glycerophosphate, 0.5 mM dithiothreitol, and 0.1 Ci of [␥-P32]ATP) for 20 min at 30 °C.
Reactions were stopped by adding 15 l of 5⫻ sample buffer,
and the samples were resolved by 10% SDS-PAGE. The phosphorylated CtBP was analyzed from dried gels with a PhosphorImager (GE Healthcare).
Western Blotting—The CtBP levels were assayed by Western
blotting with a CtBP antibody. The CtBP signal was quantified
by densitometry at the linear range of the standard curve and
expressed as arbitrary units. Results from three independent
NOVEMBER 17, 2006 • VOLUME 281 • NUMBER 46

FIGURE 1. JNK1 phosphorylates CtBP on Ser-422. A, CtBP is phosphorylated
by JNK1 in vitro. JNK1 and p38 were activated by MKK7 and MKK3 kinases and
incubated with [32P]ATP and recombinant CtBP, either the wild type (WT) or
the S422A mutant form (SA). B, constitutively active JNK1 (MKK7JNK1) caused
CtBP phosphorylation on Ser-422 in Cos 7 cells. MKK7-JNK1 and FLAG-CtBP
were transfected into Cos 7 cells, and 16 h later CtBP was assayed by Western
blot using a CtBP antibody (CtBP) or an antibody recognizing Ser-422-phosphorylated CtBP (pCtBP). C, CtBP in human non-small cell lung cancer H1299
cells was phosphorylated on Ser-422 following MKK7-JNK1 expression.

experiments were presented as mean ⫾ S.D. The anti-phospho
Ser-422 antibody was described before (19). The apoptotic
response was assayed by Hoechst dye to monitor apoptosisassociated chromatin condensation or by Western blotting
using antibodies to the active forms of caspase-3 (Cell Signaling). Antibodies to ␣-tubulin and to phospho-JNK and phospho-c-Jun were from Sigma and Cell Signaling, respectively.

RESULTS
Previously, we have demonstrated that HIPK2 activation
causes Ser-422 phosphorylation and degradation of CtBP (16).
To elucidate the role of other stress-induced signal pathways in
CtBP regulation, we screened stress-activated MAP kinases
JNK1 and p38 using an in vitro phosphorylation assay. Bacterially purified JNK1 and p38 were activated by their specific
upstream kinases (MKK7 and MKK3, respectively) and incubated with [32P]ATP in the presence of recombinant CtBP protein. Maltose-binding protein was used as positive control for
the activities of these kinases. CtBP is specifically phosphorylated by JNK1 but not p38 (Fig. 1A).
JNK1 prefers Ser/Thr residues surrounded by prolines. Ser422 of CtBP is flanked by two prolines. To test whether JNK1mediated CtBP phosphorylation is specific to Ser-422, recombinant CtBP mutant (S422A) was tested by the in vitro
phosphorylation assay. No phosphorylation signal was detected
with S422A mutant (Fig. 1A), suggesting Ser-422 is the specific
target of JNK1.
To test whether JNK1 activation contributes to CtBP Ser-422
phosphorylation in vivo, we co-expressed the constitutively
activated JNK1 and CtBP in Cos 7 cells. The active JNK is a
fusion of JNK1 and MKK7 and causes constitutive JNK1 activation in cells without stimulation (25). Our previous study
showed that Ser-422 phosphorylation is a transient event preceding CtBP clearance (19). Therefore, we assayed CtBP phosphorylation on Ser-422 16 h after the transfection. MKK7JNK1 expression caused robust Ser-422 phosphorylation on
JOURNAL OF BIOLOGICAL CHEMISTRY
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CtBP at Ser-422 (16). HIPK2 had previously been shown to
mediate the phosphorylation of p53 in response to UV irradiation, thereby activating p53 function and promoting apoptosis
(17, 18). Our studies showed that HIPK2 also promotes apoptosis through its effects on CtBP. Phosphorylation by HIPK2 targets CtBP to a proteasomal degradation pathway. The resultant
decrease in CtBP levels, like the HIPK2 activation of p53, sensitizes cells to apoptosis. UV irradiation also appears to activate
the CtBP degradation pathway and similarly promotes apoptosis in cells (including most tumor cells) that lack p53 (16).
The HIPK2 phosphorylation site on CtBP might also be recognized by other kinases. We have raised a phospho-specific
antibody to follow CtBP modification at Ser-422 in response to
UV irradiation (19) and other stimuli. This reagent allowed us
to screen additional signaling pathways that stimulate Ser-422
phosphorylation and regulate CtBP stability. The mitogen-activated protein kinase family member c-Jun NH2-terminal
kinase 1 (JNK1) plays important roles in triggering apoptosis in
response to cellular stresses such as UV irradiation and cytokines (20 –23). In this study, we found that JNK1 can phosphorylate Ser-422 of CtBP and triggers CtBP degradation. Both UV
irradiation and cisplatin induced sustained JNK activation and
decreased CtBP levels. This pathway promotes p53-independent apoptosis in tumor cells, suggesting a novel possibility for
cancer therapy by targeting JNK1-mediated CtBP degradation.

JNK Phosphorylation of CtBP Regulates Apoptosis
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stimulated conditions (19). The
MG-132 treatment largely attenuated the CtBP decrease induced by
MKK7-JNK1 (Fig. 2B), suggesting
that JNK1 activation triggers CtBP
degradation through the proteasomal pathway. The expression of the
active JNK1 in human lung cancer
H1299 cells also decreased endogenous levels of CtBP (Fig. 2C). The
evidence from both Cos 7 cell and
H1299 cells suggests that JNK1 activation triggers CtBP degradation.
JNK is a stress-induced kinase
responding to stimuli, including UV
irradiation and chemotherapeutic
drugs. We monitored JNK activation over time in H1299 cells and
found that UV-B (2000 J/m2) caused
FIGURE 2. JNK1 activation directs CtBP toward proteasomal degradation. A, CtBP levels in Cos 7 cells sustained JNK activation for up to
expressing constitutively active JNK1 (MKK7JNK1) were assayed by Western blot using a CtBP antibody (CtBP). 6 h (Fig. 3A). UV irradiation conTubulin served as a loading control. CtBP signal was quantified from three independent experiments and
expressed as arbitrary units in the bar graph. B, Cos 7 cells expressing MKK7-JNK1 were treated with the comitantly decreased CtBP levels.
proteasome inhibitor MG-132 at 2.5 M (⫹) or the carrier Me2SO (⫺). The level of CtBP was assayed by Western To test whether the JNK1 pathway
blot using an anti-CtBP antibody. C, MKK7-JNK1 decreased endogenous CtBP in H1299 lung cancer cells.
MKK7-JNK1 was transfected into H1299 cells, and 24 h later CtBP was assayed by Western blot using a CtBP is involved in the UV-induced CtBP
response, we made use of the JNK1antibody (CtBP).
null MEFs immortalized with
human papilloma viral E6 and E7 proteins (26). CtBP level
decreased following UV irradiation in the wild-type MEFs,
whereas JNK1 knock out prevented UV-triggered CtBP degradation (Fig. 3B), suggesting that JNK1 is an important mediator
for CtBP degradation in response to UV irradiation.
In addition to UV irradiation, JNK has been shown to be
activated by either TNF␣ or chemotherapeutic drugs such as
cisplatin (22). To test whether CtBP is responsive to these stimFIGURE 3. JNK1 is responsible for UV-triggered CtBP degradation. A, UV uli, H1299 cells were stimulated with 10 ng/ml TNF␣ or 1
irradiation induced sustained JNK activation and decreased levels of CtBP. g/ml cisplatin. TNF␣ caused a transient activation of the JNK
H1299 cells were irradiated by UV-B (2000 J/m2) and assayed for the phosphorylation of JNK (pJNK) and c-Jun (p-Jun) by Western blotting at 3- and 6-h signal pathway, whereas a prolonged activation of JNK was
post-irradiation. CtBP levels were also measured to correlate with JNK activa- observed after cisplatin treatment (up to 6 h) (Fig. 4A). CtBP
tion. B, JNK1 knock out prevented the CtBP degradation induced by UV irradiation. Wild-type (WT) or JNK1-null (JNK1⫺/⫺) MEFs were exposed to UV-B. degradation was only observed in cells with sustained JNK actiCtBP levels were assayed at different times after UV irradiation using an anti- vation by cisplatin but not transient JNK activation by TNF␣.
CtBP antibody. Cellular levels of ␣-tubulin remained constant.
This effect was partially blocked by JNK1 knock out (Fig. 4B),
suggesting that sustained JNK activation is required for CtBP
CtBP in Cos 7 cells (Fig. 1B). Furthermore, the expression of the degradation.
Previously, we have shown that CtBP degradation triggers
constitutively active JNK1 also strongly stimulated Ser-422
phosphorylation on CtBP in human lung cancer cells lacking apoptosis (16). We asked whether JNK1 activation in tumor
p53 (Fig. 1C), suggesting a potential link between cellular stress cells would lead to cell death as well. H1299 cells were transfected with MKK7-JNK1, and 2 days later the cells were stained
signals and CtBP regulation in human cancer cells.
Ser-422 phosphorylation of CtBP has been demonstrated to with Hoechst dye to monitor apoptosis-associated chromatin
trigger the proteasomal degradation (19); thus, we asked condensation (Fig. 5A). MKK7-JNK1 increased apoptosis in
whether activation of the JNK1 pathway induces CtBP degra- p53-null H1299 cells. One hundred cells from three random
dation. MKK7-JNK1 expression in Cos 7 cells decreased FLAG- fields were counted. The numbers of condensed nuclei are
CtBP levels (Fig. 2A). Next, we asked whether the decrease in 6.3 ⫾ 1.0 for the control versus 39.3 ⫾ 4.0 for the MKK7-JNK1CtBP levels can be inhibited by proteasomal blockage. MKK7- transfected cells.
To further evaluate the involvement of CtBP degradation
JNK1-transfected cells were treated overnight with 2.5 M
MG-132, a specific proteasome inhibitor, and their CtBP levels in JNK1-induced apoptosis, we introduced either the wildwere assayed by Western blotting (Fig. 2B). The basal CtBP type CtBP or the non-phosphorylatable S422A mutant of
level was higher in the presence of MG-132, consistent with our CtBP to H1299 cells and checked whether it would prevent
previous finding that CtBP is actively turned over even at non- the apoptosis triggered by JNK1 activation. MKK7-JNK1-

JNK Phosphorylation of CtBP Regulates Apoptosis
induced apoptosis of H1299 cells was measured by either the
cleavage of caspase 3 (Fig. 5B, left panel) or the appearance of
the condensed nuclei (Fig. 5B, right panel). As expected, the
non-phosphorylatable CtBP mutant is more resistant to degradation induced by MKK7-JNK1 (Fig. 5B, left panel). Cotransfecting the H1299 cells with S422A CtBP mutant significantly rescued apoptosis triggered by JNK1 activation (Fig.
5B), highlighting the apoptotic function of the JNK1-CtBP
pathway in human cancer cells lacking p53.

DISCUSSION

FIGURE 5. CtBP decrease by JNK1 activation triggers apoptosis of human
tumor cells. A, MKK7-JNK1 induced apoptosis in p53-null H1299 cells.
H1299 cells were transfected with MKK7-JNK1, and 2 days later the cells
were stained with Hoechst dye to monitor apoptosis-associated chromatin condensation. Left panel shows the representative image of the
Hoechst staining of H1299 cells expressing MKK7-JNK1 (MKK7JNK1) compared with the vector control (pcDNA3). One hundred cells from three
random fields were counted, and the numbers of condensed nuclei were
expressed as mean ⫾ S.D. B, the non-phosphorylatable CtBP mutant
attenuated the apoptotic response of H1299 cells transfected with MKK7JNK1. Wild type or S422A mutant (S422A) of CtBP were co-transfected with
(⫹) or without (⫺) MKK7-JNK1 (MKK7JNK1) into H1299 cells. 24 h later,
cellular apoptosis was quantified by the appearance of condensed nuclei
(right panel). CtBP content and the apoptotic marker, cleaved caspase-3
(c-caspase3), were assayed by Western blotting (left panel).
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FIGURE 4. Cisplatin induces CtBP clearance. A, H1299 cells were stimulated
with 10 ng/ml TNF␣ or 1 g/ml cisplatin. JNK phosphorylation (pJNK) and
CtBP levels were assayed over time. B, JNK1 knock out attenuated the CtBP
degradation induced by cisplatin. Wild-type (WT) or JNK1-null (JNK1⫺/⫺)
MEFs were treated with 1 g/ml cisplatin. CtBP levels were assayed 6 h later
using an anti-CtBP antibody.

Multiple pro- and anti-apoptotic molecules act in concert to
regulate commitment to apoptosis in cells; the balance between
survival and death can be tipped by the effects of single molecules such as the stress-induced p53 protein. It has been proposed that agents targeted toward p53 may be useful therapeutically for cancer. While half of the human cancers have lost the
functional p53 apoptotic pathway, the search for p53-independent tumor cell death has attracted major efforts in the cancer research field. Isolation of the cellular binding partners of
the viral transforming oncoprotein E1A has identified CtBP as a
key regulator that coordinately regulates the expression of multiple apoptosis control genes independent of p53 (27). The finding that CtBP levels can be down-regulated by JNK1 could have
implications for many transcriptional pathways that lead to cell
death.
Despite the clear indications that CtBP is critical for embryonic development and cellular transformation, little is known
about CtBP regulation. Kagey et al. (15) recently reported that
CtBP was sumoylated on lysine 428 via the actions of PC2, a
polycomb group protein. Sumoylation is believed to be important for targeting transcription factors to specific subnuclear
domains, and it is possible that this modification could contribute to the regulation of CtBP function.
The fact that CtBP is a phosphoprotein points to another
possible mode of regulation. Our previous studies indicate that
the nuclear serine/threonine kinase HIPK2 phosphorylates
CtBP at Ser-422 and directs CtBP toward degradation, inducing
cell death through a p53-independent mechanism (16, 19).
Here, we present evidence that activation of JNK1 triggers a
similar mode of CtBP regulation. JNK1 is a well known stressinduced kinase that participates in the apoptotic response.
Tumor cells are frequently deficient in functional p53 but can
still undergo apoptosis in response to chemotherapeutic drugs.
Our results suggest that CtBP depletion mediated through
JNK1 could contribute to apoptosis in this setting.
JNK1 plays important roles in triggering apoptosis in
response to cellular stresses such as UV irradiation and cytokines. JNK1 is activated through phosphorylation by MKK4
and MKK7, which convey upstream stress signals. Simultaneous disruption of the Mkk4 and Mkk7 genes in mice is
required to block JNK activation caused by exposure of cells
to environmental stress (28). Although it has been well
established that JNK activation is involved in stress-triggered apoptosis, the mechanism by which JNK activation
triggers apoptosis remains largely unknown. Our data demonstrate that JNK1 activation directs the anti-apoptotic co-

JNK Phosphorylation of CtBP Regulates Apoptosis
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CtBP degradation and the downstream targets of CtBP is
needed to enhance our understanding of transcription regulation in response to cellular stress. It may also provide therapeutic strategies and targets in cancer therapy, particularly in treating cancer with mutant p53.
Acknowledgments—We thank R. Davis for providing the JNK1-related constructs and R. H. Goodman, Y. Liu, and X.-J. Wang for helpful comments.
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repressor CtBP to clearance, thus contributing to cell death
in tumor cells.
The loss of JNK expression results in substantial increases in
the number and size of tumor nodules in vivo (29). Complementation assays demonstrated that this phenotype is caused
by JNK deficiency. Therefore, JNK may suppress tumor development by contributing to the apoptotic elimination of transformed cells (29). This conclusion is consistent with the presence in human tumors of loss-of-function mutations in the JNK
pathway (30). Mkk4 is mutated in human pancreatic, lung,
breast, colorectal, and prostate cancer (31) (32–34). Loss-offunction mutations in Mkk4 markedly reduce JNK activation
(28, 35–37) and correlate with aggressive tumor development
and metastasis (31, 34, 38 – 40). It will be interesting to monitor
CtBP levels in human tumors associated with loss-of-function
mutations in the JNK pathway.
The clearance of CtBP induced by MKK7-JNK1 is blocked by
the proteasomal inhibitor MG-132, suggesting that JNK1
directs the co-repressor CtBP to the proteasome machinery.
We demonstrated that this process depends upon JNK1
phosphorylation of CtBP at Ser-422. This residue is flanked
by prolines. Ser-422 phosphorylation of CtBP seems to mark
CtBP for proteasomal degradation. Both JNK1 and HIPK2
activation induced Ser-422 phosphorylation and CtBP degradation. Previously, HIPK2 has been shown to be activated by
UV irradiation (17, 18) and thus lead to CtBP regulation (16).
Interestingly, JNK1 knock out inhibited UV-triggered CtBP
degradation, pointing to the potential link between these two
kinases. In fact, HIPK2 has been demonstrated to activate the
JNK pathway in hepatoma cells (41). Further study is needed to
address the possible cross-talk between HIPK2 and JNK1 in
CtBP regulation and define the molecular nature of their functional connection. Whether these kinases directly phosphorylate Ser-422 in vivo and whether phosphorylation at Ser-422
affects other modifications of CtBP remains unknown.
The ability of JNK1 to regulate CtBP levels is consistent with
the finding that CtBP levels are reduced after UV exposure or
cisplatin treatment. Involvement of JNK1 in these responses
was supported by studies using the JNK1-null cells. Our study
shows that CtBP degradation is triggered by sustained JNK activation by either UV irradiation or cisplatin, whereas transient
JNK activation by TNF␣ failed to decrease CtBP levels. This is
interesting given that tumor cell derivatives that lack sustained
JNK activation are resistant to chemotherapeutic drugs (42).
Relatively little is known about the regulation of transcriptional co-activators and co-repressors by intracellular signaling
pathways. As opposed to modifications of specific DNA binding factors, phosphorylation of co-regulators has the potential
to influence a large number of transcriptional programs. Our
study demonstrated that Ser-422 on CtBP can be recognized by
the stress-induced kinases. Conceivably, activation of one of
these signaling pathways could be utilized therapeutically to
down-regulate CtBP and block the ability of factors such as
Evi-1 to mediate cell transformation. Alternatively, because
E-cadherin and other cell adhesion genes are up-regulated by
CtBP ablation, it is possible that manipulation of CtBP levels
could be used to decrease the propensity of certain tumors to
metastasize. Further characterization of the signal pathways of

JNK Phosphorylation of CtBP Regulates Apoptosis
31. Kim, H. L., Vander Griend, D. J., Yang, X., Benson, D. A., Dubauskas, Z.,
Yoshida, B. A., Chekmareva, M. A., Ichikawa, Y., Sokoloff, M. H., Zhan, P.,
Karrison, T., Lin, A., Stadler, W. M., Ichikawa, T., Rubin, M. A., and
Rinker-Schaeffer, C. W. (2001) Cancer Res. 61, 2833–2837
32. Su, G. H., Hilgers, W., Shekher, M. C., Tang, D. J., Yeo, C. J., Hruban, R. H.,
and Kern, S. E. (1998) Cancer Res. 58, 2339 –2342
33. Teng, D. H., Perry, W. L., III, Hogan, J. K., Baumgard, M., Bell, R., Berry, S.,
Davis, T., Frank, D., Frye, C., Hattier, T., Hu, R., Jammulapati, S., Janecki,
T., Leavitt, A., Mitchell, J. T., Pero, R., Sexton, D., Schroeder, M., Su, P. H.,
Swedlund, B., Kyriakis, J. M., Avruch, J., Bartel, P., Wong, A. K., Tavtigian,
S. V., and et al. (1997) Cancer Res. 57, 4177– 4182
34. Yoshida, B. A., Dubauskas, Z., Chekmareva, M. A., Christiano, T. R., Stadler, W. M., and Rinker-Schaeffer, C. W. (1999) Cancer Res. 59,
5483–5487
35. Ganiatsas, S., Kwee, L., Fujiwara, Y., Perkins, A., Ikeda, T., Labow, M. A.,
and Zon, L. I. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6881– 6886

36. Nishina, H., Fischer, K. D., Radvanyi, L., Shahinian, A., Hakem, R., Rubie,
E. A., Bernstein, A., Mak, T. W., Woodgett, J. R., and Penninger, J. M.
(1997) Nature 385, 350 –353
37. Yang, D., Tournier, C., Wysk, M., Lu, H. T., Xu, J., Davis, R. J., and Flavell,
R. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3004 –3009
38. Debies, M. T., and Welch, D. R. (2001) J. Mammary Gland Biol. Neoplasia
6, 441– 451
39. Wu, C. W., Li, A. F., Chi, C. W., Huang, C. L., Shen, K. H., Liu, W. Y., and
Lin, W. (2000) Am. J. Pathol. 156, 2007–2015
40. Yamada, S. D., Hickson, J. A., Hrobowski, Y., Vander Griend, D. J., Benson,
D., Montag, A., Karrison, T., Huo, D., Rutgers, J., Adams, S., and RinkerSchaeffer, C. W. (2002) Cancer Res. 62, 6717– 6723
41. Hofmann, T. G., Stollberg, N., Schmitz, M. L., and Will, H. (2003) Cancer
Res. 63, 8271– 8277
42. Mansouri, A., Zhang, Q., Ridgway, L. D., Tian, L., and Claret, F. X. (2003)
Oncol. Res. 13, 399 – 404

Downloaded from http://www.jbc.org/ by guest on October 14, 2016

NOVEMBER 17, 2006 • VOLUME 281 • NUMBER 46

JOURNAL OF BIOLOGICAL CHEMISTRY

34815

